Investing
Investing Cash Flow
Regeneron Pharmaceuticals Investing Cash Flow decreased by 6.5% to -$428.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 166.2%, from $647.50M to -$428.90M. Over 2 years (FY 2021 to FY 2023), Investing Cash Flow shows an upward trend with a -24.0% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
A negative value typically signals investment in future growth, while a positive value may indicate divestment or the maturity of a large investment portfolio.
Detailed definition
This metric is the net total of all cash inflows and outflows related to investing activities, including capital expendi...
Peer comparison
Most mature healthcare companies maintain a negative net investing cash flow due to ongoing R&D and infrastructure investment.
Metric ID:
net_cash_from_investingHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$2.44B | -$2.01B | -$1.71B | -$413.90M | $0.00 | -$1.86B | -$235.70M | -$2.39B | -$496.30M | -$66.20M | -$1.69B | -$557.20M | -$574.40M | $647.50M | -$1.09B | -$402.90M | -$428.90M |
| QoQ Change | — | — | +17.5% | +15.3% | +75.7% | +100.0% | — | +87.3% | -912.7% | +79.2% | +86.7% | <-999% | +67.0% | -3.1% | +212.7% | -269.0% | +63.2% | -6.5% |
| YoY Change | — | — | — | — | — | +100.0% | +7.7% | +86.2% | -476.7% | — | +96.4% | -615.8% | +76.7% | -15.7% | +138.4% | -96.3% | +29.9% | -166.2% |
Range-$2.44B – $647.50M
Avg YoY Growth-69.6%
Median YoY Growth+18.8%
Investing Cash Flow at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's investing cash flow?
- Regeneron Pharmaceuticals (REGN) reported investing cash flow of -$428.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's investing cash flow changed year-over-year?
- Regeneron Pharmaceuticals's investing cash flow decreased by 166.2% year-over-year, from $647.50M to -$428.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's investing cash flow?
- Over 2 years (2021 to 2023), Regeneron Pharmaceuticals's investing cash flow has grown at a -24.0% compound annual growth rate (CAGR), from -$5.51B to -$3.19B.
- What does investing cash flow mean?
- The net amount of cash spent on or received from investing activities.